HOME >> BIOLOGY >> NEWS
New transgenic rat model of ALS expands research possibilities

A team of scientists led by drug maker Wyeth-Ayerst and Johns Hopkins have engineered and tested a new rat model of Lou Gehrig's disease they say is far easier to work with than earlier mouse models.

Because of their larger size, the rats should expedite evaluation of novel treatments, such as those using stem cells, as well as deepen understanding of the fatal disease also known as amyotrophic lateral sclerosis (ALS), the scientists say. The "transgenic" rat, which carries a human gene, already has revealed the important role played by brain cells called astrocytes, a role obscured in mice.

The ALS rat, believed to be the first transgenic rat model of a neurodegenerative disease, moves from onset of symptoms through to ALS-like disability more quickly than ALS mice, making changes in cells in the rats more striking from day to day, the scientists report in the Jan. 29 online edition of the Proceedings of the National Academy of Sciences.

"The transgenic rats are a powerful tool," says neurologist Jeffrey Rothstein, M.D., director of the Center for ALS Research at Johns Hopkins and an author of the report. "Mice are just too small, for example, for reliable infusions into their spinal cords, the direction research on stem cell treatment is heading."

Scientists at Wyeth-Ayerst engineered the rats to carry an abnormal human gene for superoxide dismutase (SOD1), an enzyme that normally breaks down free radicals, highly reactive molecules that quickly damage DNA and kill cells. Faulty SOD1 behavior, caused by a number of different genetic mutations, is at the root of roughly one-fifth of inherited ALS cases.

The SOD1 rats, like the SOD1 mice before them, develop a disease very similar to ALS in humans, which is characterized by the death of motor nerve cells throughout the central nervous system. The rats are "symptom-free" for a longer time, but then deteriorate much more rapidly than the mice.

While the faster disease
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
28-Jan-2002


Page: 1 2 3

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. UGA researchers use transgenic trees to help clean up toxic waste site
3. Could Bt transgenic crops have nutritionally favourable effects on insects?
4. Scientists transgenic chicken aids embryo research
5. Scientists report first transgenic animal developed via retroviral DNA insertion into male germ-line stem cells
6. Eating transgenic sausages
7. Dairy scientist advances field of transgenics and knowledge of growth hormones
8. Scientists develop most efficient mouse cloning strategy to date, create transgenic clone
9. New transgenic mouse likely to advance Alzheimers disease research
10. University of Florida researchers test drug from transgenic sheep in study at Shands at UF teaching hospital
11. Jefferson scientists create first transgenic mouse model of hepatitis B-based liver disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/9/2019)... ... April 09, 2019 , ... The McLeod Center for ... following a rigorous and voluntary audit conducted by an independent, third-party panel of ... Novalis Certified Centers in the United States, McLeod is the only such cancer center ...
(Date:4/4/2019)... GALWAY, Ireland (PRWEB) , ... April 02, 2019 ... ... discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced it will move ... to become the anchor tenant at the University’s newly created biotechnology park in ...
(Date:4/4/2019)... , ... April 03, 2019 , ... ... stem cell therapies performed at its nationwide Centers of Excellence. R3 wants patients ... cell therapy provider. , To protect patients from Centers that use inferior regenerative ...
Breaking Biology News(10 mins):
(Date:4/10/2019)... ... April 10, 2019 , ... ... locked into multiple agreements to help companies advance their innovations to clinical ... ranging from synthetic biology companies that are gene editing therapeutic cells for ...
(Date:4/9/2019)... ... 09, 2019 , ... USDM Life Sciences , the ... organizations to accelerate innovation and maximize productivity, announces that nearly 100 companies have ... , USDM’s Cloud Assurance is a managed subscription service delivering end-to-end ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society of Gene & ... leadership team, including a new addition to the presidential line of succession, at the ... join the Society's leadership team for a three-year term (2019-2021). , All five incoming ...
(Date:4/8/2019)... SAN FRANCISCO (PRWEB) , ... April 08, 2019 , ... ... to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical ... dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and ...
Breaking Biology Technology:
Cached News: